BiomX Inc. — Director's Dealing 2024

Jul 18, 2024

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: BiomX Inc. (PHGE)
CIK: 0001739174
Period of Report: 2024-07-15

Reporting Person: Flynn James E (Director, Director by Deputization)
Reporting Person: DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) (Director, Director by Deputization)
Reporting Person: Deerfield Mgmt V, L.P. (Director, Director by Deputization)
Reporting Person: Deerfield Mgmt HIF, L.P. (Director, Director by Deputization)
Reporting Person: Deerfield Private Design Fund V, L.P. (Director, Director by Deputization)
Reporting Person: Deerfield Healthcare Innovations Fund II, L.P. (Director, Director by Deputization)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2024-07-15	Common Stock	M	5883000	—	Acquired	8938049	Indirect
2024-07-15	Common Stock	M	5883000	—	Acquired	8938049	Indirect

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2024-07-15	Series X Non-Voting Convertible Preferred Stock	$	M	5883	Disposed		Common Stock (5883000)	Indirect
2024-07-15	Series X Non-Voting Convertible Preferred Stock	$	M	5883	Disposed		Common Stock (5883000)	Indirect

Footnotes

F1: In accordance with the Certificate of Designation of Preferences, Rights and Limitations (the "Certificate of Designation") governing the Series X Non-voting Convertible Preferred Stock ("Series X Preferred Stock"), on July 15, 2024, 5,883 shares of Series X Preferred Stock held by each of Deerfield Private Design Fund V, L.P. ("Fund V") and Deerfield Healthcare Innovations Fund II, L.P. ("HIF II" and, together with Fund V, the "Funds") automatically converted into 5,883,000 shares of Common Stock. The acquisition or deemed acquisition of such shares of Common Stock upon such conversion, and any disposition or deemed disposition of such shares of Series X Preferred Stock upon such conversion, were exempted pursuant to Rule 16b-3 under the Securities Exchange Act of 1934, as amended.

F2: This Form 4 is being filed by the undersigned as well as the entities listed on the Joint Filer Information Statement attached as an exhibit hereto (the "Reporting Persons"). Deerfield Mgmt V, L.P. is the general partner of Fund V. Deerfield Mgmt HIF II, L.P. is the general partner of HIF II. Deerfield Management Company, L.P. is the investment manager of each Fund. James E. Flynn is the sole member of the general partner of each of Deerfield Mgmt V, L.P., Deerfield Mgmt HIF II, L.P. and Deerfield Management Company, L.P.

F3: In accordance with Instruction 4 (b)(iv) to Form 4, the entire amount of the Issuer's securities held by the Funds is reported herein. For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its indirect pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise.

F4: Each share of Series X Preferred Stock is convertible at any time at the election of the holder, subject to a beneficial ownership limitation, into 1,000 shares of Common Stock (subject to adjustment) in accordance with the Certificate of Designation. The Series X Preferred Stock has no expiration date.